Pages

Sunday, November 27, 2011

FDA Warns Fenofibric Acid (Fibricor or Trilipix) May Not Lower Heart Attack Risk.

MedPage Today Share to FacebookShare to Twitter (11/10, Gever) reports, "The FDA ordered on Wednesday that the label for fenofibric acid [Trilipix] be changed to indicate that the lipid-lowering drug has not been shown to reduce the risk of heart attack or stroke."
        HeartWire Share to FacebookShare to Twitter (11/10, Hughes) reports, "This is based on data from the ACCORD Lipid trial, in which the combination of fenofibrate plus simvastatin was compared with simvastatin alone in patients with type 2 diabetes mellitus." Based on these findings, the FDA "has requested Abbott to conduct a clinical trial to evaluate the cardiovascular effects of fenofibric acid in patients at high risk for cardiovascular disease who are already taking statins." Also covering the story are Forbes Share to FacebookShare to Twitter (11/10, Husten,) and Reuters Share to FacebookShare to Twitter

No comments:

Post a Comment